Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.4.1457

HGFK1 is Associated with a Better Prognostis and Reverses Inhibition by Gefitinib in NSCLC Cases  

Zhou, Xiao-Hui (Department of Respiratory Medicine, the First Affiliated Hospital of Soochow University)
Tang, Li-Na (Department of Oncology, Shanghai 6th People's Hospital, Shanghai Jiao Tong University)
Yue, Lu (Cancer Center, the Medical School, Hospital of Qingdao University)
Min, Da-Liu (Department of Oncology, Shanghai 6th People's Hospital, Shanghai Jiao Tong University)
Yang, Yi (Department of Thoracic Surgery, Shanghai 6th People's Hospital, Shanghai Jiao Tong University)
Huang, Jian-An (Department of Respiratory Medicine, the First Affiliated Hospital of Soochow University)
Shen, Zan (Department of Oncology, Shanghai 6th People's Hospital, Shanghai Jiao Tong University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.4, 2012 , pp. 1457-1461 More about this Journal
Abstract
Purpose: Non small cell lung cancer (NSCLC) is the leading worldwide source of cancer-related deaths. Although some drugs targeting EGFR mutations have been developed, most advanced cases are still incurable. New targets for anticancer drugs are demanded. The kringle 1 domain of hepatocellular growth factor alpha chain (HGFK1) is a potent anti-angiogenesis factor. It has also emerged as a potential anticancer factor in hepatocellular carcinoma (HCC). The expression of HGFK1 protein in patients with NSCLC has not been reported to date. Method: Here, we assessed HGFK1 expression by Western blotting in 103 cases with advanced NSCLC to investigate the impact of HGFK1 on survival. Results: Results revealed 33 (30.1%) patients were classified as high expressors, this being significantly associated with less remote metastasis (P = 0.002) but not with lymph node metastasis (P = 0.062). There was also a significant association between HGFK1 expression and tumor size (P = 0.025) as well as clinical stage (P = 0.012). Kaplan-Meier survival analysis showed that both overall survival (OS) and progression free survival (PFS) of patients with HGFK1 expression were longer than those of patients without HGFK1 expression (P = 0.004 and P = 0.001 respectively). HGFK1 reversed gefitinib inhibition in the resistent NSCLC cell line A431/GR but did not inhibit the proliferation of NSCLC cells A431 and A431/GR directly. Reversion of gefitinib inhibition in A431/GR cells by HGFK1 was related to decreased phosphorylation of ERK and STAT5. Conclusions: HGFK1 may be a useful prognostic factor of advanced NSCLC patients and a potential drug for gefitinib resistant patients.
Keywords
HGFK1 expression; non-small cell lung cancer; gefitinib resistance;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bell DW, Lynch TJ, Haserlat SM, et al (2005). Epidermal growth factor receptor mutations and gene amplification in nonsmall- cell lung cancer: molecular analysis of the IDEAL/ INTACT gefitinib trials. J Clin Oncol, 23, 8081-92.   DOI
2 Cappuzzo F, Hirsch FR, Rossi E, et al (2005). Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst, 97, 643-55.   DOI
3 Chorostowska-Wynimko J, Szpechcinski A (2007). The impact of genetic markers on the diagnosis of lung cancer: a current perspective. J Thorac Oncol, 2, 1044-51.   DOI
4 Ciardiello F, Tortora G (2008). EGFR antagonists in cancer treatment. N Engl J Med, 358, 1160-74.   DOI
5 Engelman JA, Zejnullahu K, Mitsudomi T, et al (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039-43.   DOI   ScienceOn
6 Fukuoka M, Yano S, Giaccone G, et al (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol, 21, 2237-46.   DOI   ScienceOn
7 Gschwind A, Fischer OM, Ullrich A (2004). The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer, 4, 361-70.   DOI
8 Guo R, Chen X, Wang T, et al (2011). Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer, 11, 90.   DOI   ScienceOn
9 Hynes NE, Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 5, 341-54.   DOI   ScienceOn
10 Kim ES, Hirsh V, Mok T, et al (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 372, 1809-18.   DOI   ScienceOn
11 Kosaka T, Yamaki E, Mogi A, et al (2011). Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol, 2011, 165214.
12 Kris MG, Natale RB, Herbst RS, et al (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 290, 2149-58.   DOI   ScienceOn
13 Li D, Ambrogio L, Shimamura T, et al (2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 27, 4702-11.   DOI   ScienceOn
14 Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39.   DOI   ScienceOn
15 Mahata S, Bharti AC, Shukla S, et al (2011). Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells. Mol Cancer, 10, 39.   DOI
16 Moyer JD, Barbacci EG, Iwata KK, et al (1997). Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res, 57, 4838-48.
17 Nie B, Shen Z, Wen JB, et al (2008). AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer. Mol Cancer Ther, 7, 2855-65.   DOI
18 Pao W, Miller V, Zakowski M, et al (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A, 101, 13306-11.   DOI   ScienceOn
19 Nishimura Y, Yoshioka K, Bereczky B, et al (2008). Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line. Mol Cancer, 7, 42.   DOI
20 Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500.   DOI   ScienceOn
21 Perez-Soler R, Chachoua A, Hammond LA, et al (2004). Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol, 22, 3238-47.   DOI   ScienceOn
22 Sharma SV, Bell DW, Settleman J, et al (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 7, 169-81.   DOI   ScienceOn
23 Shen Z, Wong OG, Yao RY, et al (2008a). A novel and effective hepatocyte growth factor kringle 1 domain and p53 cocktail viral gene therapy for the treatment of hepatocellular carcinoma. Cancer Lett, 272, 268-76.   DOI
24 Shen Z, Yang ZF, Gao Y, et al (2008b). The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma. Cancer Res, 68, 404-14.   DOI
25 Tang Z, Du R, Jiang S, et al (2008). Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer, 99, 911-22.   DOI   ScienceOn
26 Xin L, Xu R, Zhang Q, et al (2000). Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis. Biochem Biophys Res Commun, 277, 186-90.   DOI
27 Tsao MS, Sakurada A, Cutz JC, et al (2005). Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med, 353, 133-44.   DOI   ScienceOn